Advertisement


Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Advertisement